A Phase 1 Study of ABBV-706 in People With Solid Tumors


Full Title

A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors


Researchers want to find the best dose of ABBV-706 to use in people with solid tumors. The people in this study have solid tumors that came back or kept growing even after treatment. 

ABBV-706 is called an antibody-drug conjugate. The antibody part attaches to certain proteins on cancer cells. When this binding happens, the chemotherapy drug part of ABBV-706 is released. It enters the cancer cells and destroys them without harming other cells. ABBV-706 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a solid tumor that came back or kept growing after treatment.
  • Have recovered from the serious side effects of prior therapies before getting ABBV-706.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please have your oncologist call Dr. Noura Choudhury’s office at 646-608-3762.




Phase I (phase 1)

Disease Status

Relapsed or Refractory




ClinicalTrials.gov ID